Back to Search
Start Over
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
- Source :
- Annals of the Rheumatic Diseases, Repositório Científico de Acesso Aberto de Portugal, Repositório Científico de Acesso Aberto de Portugal (RCAAP), instacron:RCAAP, Lindström, U, Di Giuseppe, D, Delcoigne, B, Glintborg, B, Möller, B, Ciurea, A, Pombo-Suarez, M, Sanchez-Piedra, C, Eklund, K, Relas, H, Gudbjornsson, B, Love, T J, Jones, G T, Codreanu, C, Ionescu, R, Nekvindova, L, Závada, J, Atas, N, Yolbas, S, Fagerli, K M, Michelsen, B, Rotar, Tomšič, M, Iannone, F, Santos, M J, Avila-Ribeiro, P, Ørnbjerg, L M, Østergaard, M, Jacobsson, L T H, Askling, J & Nissen, M J 2021, ' Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration ', Annals of the Rheumatic Diseases, vol. 80, no. 11, 220097, pp. 1410-1418 . https://doi.org/10.1136/annrheumdis-2021-220097
- Publication Year :
- 2021
- Publisher :
- BMJ Publishing Group, 2021.
-
Abstract
- © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.<br />Background: Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains unclear. We aimed to compare treatment outcomes in patients with PsA treated with TNFi and csDMARD comedication versus TNFi monotherapy. Methods: Patients with PsA from 13 European countries who initiated a first TNFi in 2006-2017 were included. Country-specific comparisons of 1 year TNFi retention were performed by csDMARD comedication status, together with HRs for TNFi discontinuation (comedication vs monotherapy), adjusted for age, sex, calendar year, disease duration and Disease Activity Score with 28 joints (DAS28). Adjusted ORs of clinical remission (based on DAS28) at 12 months were calculated. Between-country heterogeneity was assessed using random-effect meta-analyses, combined results were presented when heterogeneity was not significant. Secondary analyses stratified according to TNFi subtype (adalimumab/infliximab/etanercept) and restricted to methotrexate as comedication were performed. Results: In total, 15 332 patients were included (62% comedication, 38% monotherapy). TNFi retention varied across countries, with significant heterogeneity precluding a combined estimate. Comedication was associated with better remission rates, pooled OR 1.25 (1.12-1.41). Methotrexate comedication was associated with improved remission for adalimumab (OR 1.45 (1.23-1.72)) and infliximab (OR 1.55 (1.21-1.98)) and improved retention for infliximab. No effect of comedication was demonstrated for etanercept. Conclusion: This large observational study suggests that, as used in clinical practice, csDMARD and TNFi comedication are associated with improved remission rates, and specifically, comedication with methotrexate increases remission rates for both adalimumab and infliximab.
- Subjects :
- Male
Placebo-controlled study
Psoriatic
PLACEBO-CONTROLLED TRIAL
THERAPY
Etanercept
DOUBLE-BLIND
0302 clinical medicine
Immunology and Allergy
Medicine
030212 general & internal medicine
skin and connective tissue diseases
Remission Induction
Middle Aged
Tumour necrosis factor inhibitors
Treatment Outcome
arthritis
Antirheumatic Agents
Drug Therapy, Combination
Female
medicine.drug
musculoskeletal diseases
Adult
medicine.medical_specialty
Immunology
Psoriatic Arthritis
tumour necrosis factor inhibitors
General Biochemistry, Genetics and Molecular Biology
methotrexate
03 medical and health sciences
Psoriatic arthritis
Rheumatology
Internal medicine
Adalimumab
Humans
030203 arthritis & rheumatology
business.industry
Arthritis
Arthritis, Psoriatic
EFFICACY
medicine.disease
Infliximab
Discontinuation
Methotrexate
3121 General medicine, internal medicine and other clinical medicine
Tumor Necrosis Factor Inhibitors
psoriatic
business
Subjects
Details
- Language :
- English
- ISSN :
- 14682060 and 00034967
- Volume :
- 80
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Annals of the Rheumatic Diseases
- Accession number :
- edsair.doi.dedup.....022e520d9e5e31bc0cc0baf6321a0476